Marcan Pharmaceuticals Acquires Class E Special Shares in Mantra Pharma Inc. for CAD $50 Million
Emcure Pharmaceuticals Ltd's subsidiary, Marcan Pharmaceuticals Inc., has entered into a share purchase agreement to acquire all of the Class E Special Shares of Mantra Pharma Inc., completing a significant transaction within its steps-down subsidiary structure. The acquisition was finalized on July 2, 2026.Mantra Pharma Inc., which operates in Canada and focuses on the marketing and distribution of prescription drugs and natural health products, is one of the entities involved. Marcan Pharmaceuticals Inc. purchased all Class E Special Shares from certain shareholders of Mantra. Following this purchase, Mantra remains a wholly-owned subsidiary of Marcan.
The acquisition constituted a related party transaction between two wholly-owned subsidiaries and was undertaken on an arm's length basis. Mantra Pharma Inc., incorporated under the laws of Quebec, Canada, is primarily engaged in the pharmaceuticals industry.
Mantra holds a position within the Canadian market, having been formed on November 6, 2023, through amalgamation involving multiple entities. The company has maintained a trajectory of growth in terms of turnover over its past three financial years.
The historical turnover figures for Mantra Pharma Inc. are detailed below:
| Financial Year | Turnover (CAD) |
|---|---|
| Financial Year 2026 | CAD $ 96.67 million |
| Financial Year 2025 | CAD $ 81.01 million |
| Financial Year 2024 | CAD $ 28.26 million |
The transaction involved a cash consideration amounting to an aggregate cost of CAD $50 million for the acquisition of 100% of the Class E Special Shares in Mantra Pharma Inc.
EMCURE Stock Price Movement
As of 10:06 AM, shares of Emcure Pharmaceuticals Limited are slipping by 0.69%, trading at ₹1843.7 following a decline of ₹12.80. The stock remains active in the market, having traded within an intraday range between a low of ₹1840.2 and a high of ₹1860.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.